Value Hive Podcast cover image

Q3 2022 Investor Audibles: Third Point Capital, Ensemble Capital, Greenlight Capital

Value Hive Podcast

00:00

Third-Path Investing in Ventix

Ventix is a biotechnology company focused on treating autoimmune diseases by discovering and developing next-generation small molecule drugs for well-validated targets. Third-point first invested in Ventix in 2016 as an investment in Opelian, which was developing in an oral small molecule for ulcerative colitis with a post-money valuation of roughly $20 million. In early 2021, third-point along with management agreed to merge our opelian investment into Ventix to consolidate all autoimmune disorder assets run by the same management team under one company. We found the consolidated R&D pipeline, especially Ventix's TYK2 inhibitor commercially very attractive. The merger allowed the company to bulk

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app